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Introduction: Data on epidemiology of HPV infection are needed for the development of
human papillomavirus (HPV) vaccine recommendations, especially in countries where
HPV vaccination is not yet included in public vaccination programs. The aim of this study
was to determine the prevalence of serum antibodies to HPV types 6, 11, 16, and 18 and
associated factors among young women after birth of the ﬁrst child.
Methods: This cross-sectional study was carried out in a large public maternity hospital in
Sao Paulo, Brazil. Three hundred one women aged 15 to 24 years who gave birth to their
ﬁrst child were recruited between 43 and 60 days after delivery. Seroprevalence was per-
formed using a type-speciﬁc enzyme-linked immunosorbent assay based on HPV L1AQ2 vir-
uslike particles. The association of seroreactivity with these 4 HPV types with selected
demographic and behavioral factors was assessed by Generalized Linear Model analysis.
Results: Fifty-eight (19.3%) women (95% conﬁdence interval, 15.0%Y24.2%) had anti-
bodies to any of the 4 viruslike particles tested. The overall seroprevalence ratesAQ3 of the
HPV types were: HPV16, 9.0%; HPV18, 7.0%; and HPV6+11, 7.4%, which are targeted by
the HPV prophylactic vaccines. In the multivariate analysis, only age (inversely, P = 0.044
for trend) and previous sexually transmitted disease (P = 0.008) were 2 factors indepen-
dently associated with HPV seropositivity.
Conclusions: These data offer additional information on the epidemiology of HPV in a
group of young Brazilian women after ﬁrst delivery and contribute to establish a baseline of
HPV seroprevalence against which postYHPV vaccine era seroprevalence can be compared.
Key Words: HPV serology, VLP antibodies, Cervical cancer, HPV immunization,
Sexually transmitted disease
Received May 31, 2010, and in revised form July 23, 2010.
Accepted for publication July 25, 2010.
(Int J Gynecol Cancer 2010;00: 00Y00)
Worldwide, approximately 80% of cervical cancer casesaffect women in developing countries; in Brazil ap-
proximately 20,000 cervical cancer cases occur each year,
and the number of cervical cancer deaths remains high.1
Genital infection by oncogenic human papillomavirus
(HPV) is a necessary factor in the development of cervical
cancer and HPV types 16 and 18 were identiﬁed in approx-
imately 70% of all cervical cancer cases.2
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Epidemiological studies have shown that whereas de-
tection of HPV DNA does not provide information on women
who were infected but cleared the HPV, seroprevalence
data can provide a better estimate of cumulative exposure to
HPV. However, it could also be an underestimate because
only approximately 50% of those infected with HPV have
detectable antibodies.3 Humoral anti-HPV immune responses
measured by enzyme-linked immunosorbent assay (ELISA)
using HPV typeYspeciﬁc viruslike particles (VLPs) as anti-
gens have been used for seroprevalence studies in several
countries.4
The principal application of anti-HPV serology is mon-
itoring anti-HPV vaccination.5 In addition, data on the epi-
demiology of HPV infection are needed for the development
of vaccine recommendations. In countries where HPV vac-
cination is not yet included in public vaccination programs,
estimates of seroprevalence can provide information on the
natural history of HPV infections to establish recommen-
dations on suitable age groups that can beneﬁt from the
vaccination.
Young women from low-income groups are at signiﬁ-
cantly higher risk than those from higher-income groups of
infection with HPV and cervical cancer.6 Importantly, young
age at ﬁrst delivery has been also identiﬁed as a risk factor
for cervical cancer development.7
Therefore, the aim of this study was to determine the
seroprevalence of speciﬁc HPV types and the risk factors
associated with HPV seropositivity after the delivery of the
ﬁrst child among young women in a public maternity hospital
in the city of Sa˜o Paulo, Brazil that serves mostly low-income
people from adjacent areas.
MATERIALS AND METHODS
This study was conducted at Hospital Maternidade
Leonor Mendes de Barros, one of the largest public maternity
hospitals in the city of Sao Paulo, Brazil. All primiparous
women between 15 and 24 years who had been living in the
metropolitan area of Sao Paulo for at least 6 months and gave
birth at this hospital after more than 32 weeks of gestation
were eligible for this study. The study protocol was submitted
and approved by the National Ethical Committee (number
188/2006).
This study is part of a cross-sectional study carried out
from June 2006 to February 2007 and previously published.8
The following exclusion criteria were applied: non-Brazilian,
inability or refusal to give informed consent, and immuno-
deﬁciency (including acquired immunodeﬁciency syndrome/
human immunodeﬁciency virus infection checked in medical
records).
Women were recruited to take part in this study during
the postdelivery follow-up period in the hospital. Eligible
women were contacted by a health professional (a nurse or a
physician) and asked whether they wanted to know about a
study on prevention of cervical cancer; those interested had
a postnatal visit scheduled within 43 to 60 days after de-
livery to be enrolled in the study. Women had to attend the
postnatal visit and sign the informed consent form before
being included in the study (women younger than 18 years
were also required a written consent from their parents or
legal representative).
Data and Specimen Collection
During the routine postnatal visit, women were enrolled
and interviewed using a structured epidemiologic questionnaire
that included information about demographic characteristics,
sexual behavior, reproductive history, contraceptive practice,
and smoking habits. Variables known or suspected to be related
to cervical cancer and HPV infection were included in the
questionnaire, such as age, ethnicity, education, marital status,
income (the approximate amount earned per month, summing
up all the family wages), smoking habits (current smoker: a
person who smokes at least one cigarette a day for 1 year or
more; former smoker: a person who stopped to smoke at least
1 year before the interview), age at ﬁrst sexual intercourse,
lifetime number of sexual partners, previous sexually trans-
mitted disease (any sexually transmitted disease referred by
women in the interview), previous miscarriage/abortion, con-
traception use, condom use (male or female condom), and
hormonal contraception use (oral or injectable).
After the interview, approximately 10 mL of blood
sample was taken by a nursing assistant and processed by
centrifugation at the collection site, and the serum specimen
was frozen at j20-C and transferred to the Ludwig Institute
for Cancer Research in Sao Paulo to perform serological assays
to HPV.
HPV Serology
The presence of IgG antibodies to HPV6, HPV11,
HPV16, and HPV18 in the serum samples was detected
with a type-speciﬁc ELISA using AQ2L1 VLPs synthesized in
Saccharomyces cerevisiae9 provided by Dr Ian Frazer (Uni-
versity of Queensland, Woolongaba, Australia). Fifty mi-
croliters of a solution with 0.03 mg/mL of HPV VLPs in
phosphate-buffered saline (PBS) were used to coat each well
of the ELISA plates (96 Maxisorp ELISA plates, Nunc AQ5)
overnight (14Y20 hours) at 4-C. To every 2 wells coated with
VLP, one was ﬁlled with PBS, pH 7.2. The plates were then
washed once with PBST AQ6(0.02% Tween in PBS, pH 7.2)
and blocked with 100 HL of bovine serum albumin (BSA)
blocking solution (1.5% of BSA in PBS, pH 7.2) for 2 hours.
After the blocking step, plates were washed twice with PBST.
Sera and control samples, diluted 1:50 with 5% fat-free milk
powder and 0.1% BSA in PBST, were tested in duplicates
and incubated at 37-C for 1 hour. The plates were washed 5
times with PBST, pH 7.2 and tested with horseradish per-
oxidase conjugated with antihuman IgG (Tago AQ7Immunolo-
gicals). After 45 minutes of incubation at 37-C, the plates
were washed 5 times with PBST pH 7.2 and 50 HL of AQ8ABTS
solution (0.05% 2.2¶-Azino-bis (ethylenebenzthiazoline-6-
sulfonic acid, AQ9Sigma) was added to each well. The reaction
was stopped after 4 minutes by adding 50 HL of 1% sodium
dodecyl sulfate. Optical density (OD) was read at 415 nm in a
microplate reader ( AQ10Biorad). The OD value of the serum was
calculated by subtracting the mean OD of the wells coated
with HPV L1 VLP from the OD of the wells coated with PBS.
For quality control and cutoff evaluation, we used
positive and negative serum sample controls provided by the
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World Health Organization in the WHO Workshop 2003.10
The mean and 2 SDs (standard deviations) of absorbance
values for HPV6, HPV11, HPV16, and HPV18 were calcu-
lated, and values greater than the mean plus 2 SDs were
excluded. The cutoff points for seropositivity to HPV6,
HPV11, HPV16, and HPV18 were 0.54 or greater, 0.37 or
greater, 0.13 or greater, and 0.1 or greater, respectively.
Statistical Analysis
Detection rates of HPV antibody using a VLP-based
ELISA were described as percentages with 95% conﬁdence
intervals (95% CI). To estimate the association of HPV an-
tibody detection with selected risk factors, prevalence ratios
(PR) and 95% CI were calculated, with HPV antibody de-
tection as the dependent variable and various exposure factors
as independent variables. Most independent variables were
grouped into 2 or more categories. For ordered (categorical)
exposure, variables tests for linear trend (W2 trend) in the PR
were conducted by categorizing the exposure variables and
entering the continuous scores. Variables selected in univar-
iate analysis at a 0.20 signiﬁcance level were included in
the multivariate analysis. Prevalence ratios and their 95% CI
were estimated using a Generalized Linear Model with bi-
nomial distribution and log link function.11 Statistical sig-
niﬁcance was assessed using the likelihood ratio test. A
2-sided P G 0.05 was considered to indicate statistical sig-
niﬁcance. All analyses were performed using STATAversion
8.2 (STATA).
RESULTS
A total of 509 women were invited to participate: 24
refused, 163 women previously interested in participating did
not return to the postnatal visit, and 322 attended the post-
natal visit. However, 18 women were not eligible (11 attended
the postnatal visit after 60 days from delivery, one had human
immunodeﬁciency virusYpositive serological ﬁnding, one had
more than one delivery and 5 were older than 24 years). Three
eligible women were not included in the study: one had an
acute infectious disease and 2 were younger than 18 years,
lived in a reformatory, and had difﬁculty obtaining a legal
representative signature of the informed consent form within
the study period. Therefore, 301 primiparous women were in-
cluded in this analysis.
We compared participants and no respondents by
using medical hospital records. No statistically signiﬁcant
differences were found regarding age (P = 0.205), marital
status (P = 0.480), smoking habits (P = 0.183), prenatal
health care (P = 0.436), and number of prenatal health care
visits (P = 0.214).
The mean age of the study participants was 20 years;
more than 60% were white and more than 80% were married
or living with a partner. Almost a quarter of the study parti-
cipants reported ﬁrst sexual intercourse earlier than 15 years
of age, and 40% reported only one lifetime sexual partner.
Fifty-eight (19.3%) women had antibodies to any of the
4 VLPs tested (95% conﬁdence interval [CI], 15.0%Y24.2%).
The seroprevalence of HPV16 was higher than those of the
other 3 types: 18, 11, and 6.
Antibodies to HPV types 16 and 18, high-risk types
present in both bivalent and quadrivalent HPV vaccines,
were detected in 9.0% and 7.0% of the study participants,
and antibodies to low-risk types HPV6 and/or 11, present in
the quadrivalent HPV vaccine, were detected in 7.7% of the
study participants ( T1Table 1).
Forty-six (15.3%) women were positive for a single
HPV type antibody, 11 (3.7%) women had antibody for
2 HPV types, and only one (0.3%) woman had antibody for
3 HPV types of the 4 VLPs tested. Three (1%) and two
(0.7%) participants had evidence of concomitant antibody
by both high-risk types (HPV16 and HPV18) and by both
low-risk types (HPV6 and HPV11), respectively. No woman
was seropositive for all the 4 types present in the quadriva-
lent vaccine as detected by our assay.
Prevalence ratios for HPVantibody detection according
to sociodemographic characteristics and smoking habits are
shown in T2Table 2. Human papillomavirus seroprevalence
decreased with increasing age (P = 0.078 for trend). Women
with more years of schooling had lower prevalence than
those with 7 or less years of schooling (P = 0.034).
Regarding sexual behavior, reproductive character-
istics, and contraception history, only ever having a sexually
transmitted disease (STD) was associated with HPVantibody
detection (PR, 2.40; 95% CI, 1.11Y5.19; T3Table 3).
Ethnic group, marital status, income, smoking habits,
age at ﬁrst sexual intercourse, number of lifetime sexual
partners, previous miscarriage/abortion, use of contraception,
condom, or hormonal contraception were not associated to
HPV antibody detection positivity (Tables 2 and 3).
All selected variables (age, years of schooling, and
previous STD) were included in the multivariate analysis
model. However, when age and years of schooling were
included, the model did not converge. Then, the variable
years of schooling was taken out. The multivariate analysis
TABLE 1. Seroprevalence of 4 common HPV types
among 301 young primiparous women, Sao Paulo,
Brazil, 2006Y2007
HPV Serology N %
Negative 243 80.7
Positive 58 19.3
One HPV antibody
16 27 9.0
18 21 7.0
6 15 5.0
11 8 2.7
2 HPV antibodies
11 and 16 4 1.3
16 and 18 3 1.0
6 and 11 2 0.7
6 and 18 2 0.7
3 HPV antibodies
6, 16, and 18 1 0.3
AQ12
AQ11
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revealed that only age (P =0.044 for trend) and STD
(P = 0.008) were independently associated with HPV sero-
prevalence. The prevalence ratio of HPV seropositivity for
women aged 19 to 21 years was 0.84 (95% CI, 0.50Y1.42)
and that for women 22 to 24 years old was 0.51 (95% CI,
0.27Y0.99) as compared with the women aged 15 to 18 years.
The women who reported ever having an STD were more
likely to be HPV antibody positive (PR, 2.81; 95% CI,
1.31Y6.05) compared with the women who never had a pre-
vious STD.
DISCUSSION
The seroprevalence of any HPV types 6, 11, 16, and
18 found in the young primiparous women included in the
present study was 19%. These results are within the range of
seroprevalence for these 4 HPV types reported also in young
women in other surveys, varying from 13% to 25%.12Y14 The
HPV16 (9%), HPV18 (7%), and the combined HPV6+11
(8%) seroprevalence found in the present study were similar
to those recently reported in 2 population-based surveys in
women 14 to 24 years old in the United States14 and Aus-
tralia15, and in England (women 10Y29 years old)12 varying
from 6% to 12% for HPV16, 2% to 5% for HPV18, and 9%
to 13% for HPV6+11 .
TABLE 2. Prevalence ratios and corresponding 95%
CI for seroprevalence of any of HPV types 6, 11, 16,
and 18 according to selected sociodemographic
characteristics and smoking among 301 young
primiparous women, Sao Paulo, Brazil, 2006Y2007
Total
HPV+
(%) PR 95% CI P
Age, yrs 0.078‡
15Y18 90 23.3 1
19Y21 119 21.0 0.90 (0.54Y1.50)
22Y24* 92 13.0 0.56 (0.29Y1.07)
Ethnic group 0.581
White 190 18.9 1
Black 31 12.9 0.68 (0.67Y1.33)
Mulatto 77 23.4 1.23 (0.87Y1.33)
Indian 3 V
Years of schooling 0.034‡
e7 37 29.7 1
8 67 19.4 0.65 (0.33Y1.31)
9Y10 64 23.4 0.79 (0.41Y1.53)
11 124 15.3 0.52 (0.27Y0.98)
911 9 V V
Marital status 0.937
Living with
partner
245 19.2 1
Single 56 19.6 1.02 (0.57Y1.84)
Income† 0.668‡
G1 13 38.5 1
1Y3 188 16.5 0.43 (0.20Y0.92)
4Y6 80 21.3 0.55 (0.25Y1.24)
7Y10 11 18.2 0.47 (0.11Y1.97)
910 5 40.0 1.04 (0.29Y3.72)
Smoking habits 0.648
Never 231 18.6 1
Former 20 15.0 0.81 (0.27Y2.37)
Current 50 24.0 1.29 (0.73Y2.26)
*Includes 6 women whowere 24 years old when invited but were
25 years old when they answered the questionnaire and collected
biological specimens.
†Number of minimum wages per month (one minimum wage,
R$250.00 or US$119.80; US$1.00 = R$ 2.09; Feb/2007). Data for
4 participants were missing.
‡W2 for trend.
TABLE 3. Prevalence ratios and corresponding 95%
CIs for seroprevalence of any of HPV types 6,11,16,
and 18 according to selected sexual behavior,
reproductive characteristics, and history of
contraception among 301 young primiparous women,
Sao Paulo, Brazil, 2006Y2007
Total
HPV+
(%) PR 95% CI P
Age at first sexual intercourse, yrs 0.465†
e14 72 22.2 1
15Y18 188 18.6 0.84 (0.50Y1.42)
918 41 17.1 0.77 (0.34Y1.71)
No. lifetime sexual partners 0.379†
1 120 20.0 1
2Y3 116 13.8 0.69 (0.39Y1.23)
Q4 65 27.7 1.38 (0.81Y2.36)
Previous STD 0.073
No 292 18.5 1
Yes 9 44.4 2.40 (1.11Y5.19)
Previous miscarriage/abortion 0.769
0 282 19.1 1.00
1Y2 19 21.1 1.10 (0.45Y2.71)
Contraception 0.443
Yes 227 20.3 1
No 74 16.2 0.80 (0.45Y1.43)
Condom use* 0.363
Yes 127 18.1 1
No 100 23.0 1.27 (0.76Y2.13)
Hormonal contraception* 0.727
Yes 148 20.9 1
No 79 19.0 0.91 (0.52Y1.58)
*Only women who reported ever use of contraception.
†W2 for trend.
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The prevalence of HPV infection in Latin America
is the highest in the world. In female subjects (16Y24 years
old) from 5 Latin American countries (Brazil, Costa Rica,
Guatemala, Mexico, and Peru), the overall seroprevalence
(25%) and the baseline seroprevalence of the 4 HPV vaccine
types (ie, HPV16, 14%; HPV18, 4%; HPV6+11, 13%) were
slightly higher than the seroprevalence found in the present
study, except for HPV18.13
However, the frequency of HPV18 seropositive indi-
viduals (7%) found in the present study is consistent with
reports from Costa Rica (13% in women 18Y24 years).16
In addition, a higher HPV16 and/or HPV18 combined sero-
prevalence (28%) was previously reported in Brazilian women
(15Y25 years).17
In Brazil, another study revealed an even higher overall
HPV6, HPV11, HPV16, and HPV18 seroprevalence (39%)18
than that of the present study. However, that study included
participants notably of different age groups, and the age of
participants was substantially higher (15Y70 years old)18 than
that in our study. Therefore, a plausible hypothesis to explain
this difference in seroprevalence of HPV would be different
exposures to HPV in successive Brazilian birth cohorts.
Women were enrolled in the present study within 43 to
60 days after delivery and thus were under the physiologi-
cal processes established during pregnancy that modify the
host-immune response and hormonal status. Interestingly, in
a similar study conducted in primiparous women (e30 years
old) from Finland, the reported HPV16 seroprevalence was
24% for 2 periods of analysis (1983 and 1990).19
It is very important to stress that the accuracy of HPV
serological measures are affected by the type of assay used
and the associated seropositivity cutoff values. Therefore, it
is often very difﬁcult to compare results from different epi-
demiological studies.4 There are current efforts by the World
Health Organization to develop HPV type 16 and HPV type
18 serological reference standards, as well as an agreed
deﬁnition of what level of response indicates effective sero-
reactivity.10 Moreover, the diagnostic techniques used in
different studies and the discrepancies in HPV seroprevalence
results also depend on the age of participants, the clinical
history of the women included in the study (immunodeﬁ-
ciency, abnormal cervical cytology), and on sexual patterns
accepted in each population.
Approximately 4% of women in the present study were
seropositive for at least 2 HPV types, 1% was seropositive
for both HPV16 and HPV18, and 0.7% was seropositive for
both HPV6 and HPV11, and none had simultaneous anti-
bodies to all 4 HPV types. The latter observation suggests
that most of these young women after ﬁrst delivery could still
draw beneﬁt from catch-up HPV vaccination and protection
against cervical cancer.
It is not clear whether naturally acquired HPV anti-
body responses to an HPV type provide protection against
reinfection or subsequent infection due to related types.15
In addition, serologic measurements may not identify all
immune reactive persons because approximately 50% of
HPV-infected women do not show evidence of seroconver-
sion but may nevertheless be protected against subsequent
infection.3
Serological results suggest that anti-VLP antibodies de-
tection is strongly asynchronous with infection; they are found
in approximately 10% to 20% of infected individuals at the
time that HPV DNA is detectable, and they are detected pri-
marily in association with persistent infections.5 Similarly, low
rates of concordance between the presence of HPV DNA in
primiparous young women8 and serological results in this
study have been observed. In our previous publication, with
this same population of study, 17.3% of the women were
positive for any of the 4 HPV types (HPV6, HPV11, HPV16,
or HPV18), and the overall prevalence of the HPV types
was HPV16, 12.0%; HPV18, 2.3%; and HPV6+11, 4.3%.8
One limitation of this study is that 32% of eligible
women, previously interested to participate, did not return to
the postnatal visit. The likely reason for the relatively large
number of women not attending the postnatal visit at our
hospital is the availability of postnatal services in public
health care centers near their homes, and therefore, women
may have preferred those for practical reasons. However,
participating and no participating women did not differ as
analyzed according to several factors, and this limitation is
unlikely to have affected our results signiﬁcantly.
We also studied the relationship between HPV seropos-
itivity and several risk factors for cervical cancer. The multi-
variate analysis highlights 2 associated factors with HPV
seropositivity: the history of STDs and age (inversely asso-
ciated with HPV seroprevalence). In this respect, Hagensee
et al20 reported that history of Neisseria gonorrhoeae infection
was associated with an increased seroprevalence of HPV16.
Other investigations reported that HPV seropositivity is
strongly associatedwithmarkers of sexual activity, mainly with
a woman’s elevated number of lifetime sexual partners. This
last factor is strongly associated with the presence of HPV16
antibodies16,20 as much as any HPV6, HPV11, HPV16, or
HPV18 14,18 antibodies detection. However, we did not ﬁnd
association with the number of lifetime sexual partners and
HPV seropositivity.
Age was associated with HPV seropositivity in several
studies. We have observed a trend of decreasing HPV sero-
prevalence with increasing age speciﬁc to this group of young
women, whereas other studies showed highest seroprevalence
rates in older women.12,14 These previous studies included
participants who had a higher age range (10Y29 years12 and
14Y59 years14) than the present study. However, in agreement
with our ﬁndings, another study reported that antibody levels
are likely to wane over time.3
Despite the highlighted limitations of this study, data
presented here offer unique information on the epidemiology
of HPV in young primiparous women in Brazil, a group of
women at high risk of HPV infection, who belong to an
age group eligible for catch-up HPV vaccination. Moreover,
it may set a basis to establish a baseline of HPV sero-
prevalence against which postYvaccine era seroprevalence
can be compared.
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